Reports related to this article:
Project(s): View 1 related project in PECWeb
Released October 30, 2019 | beijing
en
Jiangsu Zenji (Zhengji) Pharmaceutical will ratchet up its capital expenditures next year to $155 million, executives with the specialty producer said recently. Permitting was finalized during the fourth quarter for the company's planned active pharmaceutical ingredients (Levocarnitine Oral Solution, DL-Thioctic acid) grassroot plant in Shandong, China.
